Skip to main content
Erschienen in: Supportive Care in Cancer 11/2012

01.11.2012 | Original Article

Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting

verfasst von: Gerald M. Higa, Miklos L. Auber, Gerry Hobbs

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Besides chemotherapy drugs, a number of patient-related factors (i.e., gender, age, history of alcohol consumption, and/or motion sickness) may be used to calculate the risk for chemotherapy-induced vomiting. We evaluated data with the intent of identifying a unique variable associated with delayed vomiting in patients receiving moderately emetogenic chemotherapy (MEC).

Methods

From an ongoing research study, the serotonin metabolite, 5-hydroxyindole acetic acid (5-HIAA), creatinine, and substance P were measured over a 72-h period in 25 patients receiving MEC. All patients were treated with a 5-hydroxytryptamine-3 receptor antagonist plus dexamethasone according to published guidelines; none received aprepitant prophylactically. Urine 5-HIAA/creatinine and serum substance P values were grouped according to the development (+) or absence (−) of delayed emesis. Baseline mean values associated with the two neurotransmitters were analyzed by analysis of variance.

Results

Eleven patients developed moderate to severe delayed vomiting; the other 14 were symptom-free. The pretreatment log (mean 5-HIAA/creatinine) was 1.22 and 1.81 in the (+) and (−) emesis groups, respectively, p = 0.0049; the pretreatment log (mean substance P) for the same respective groups was 5.33 and 4.09 pg/mL, p > 0.05. The log (mean ratio of substance P to 5-HIAA/creatinine) between-group difference in those with and without emesis was 4.53 and 2.52, respectively, p = 0.0002. The 5-HIAA/creatinine and ratio of substance P to 5-HIAA/creatinine data were also used to determine cutoff points which resulted in the optimal predictive accuracy.

Conclusions

These preliminary findings suggest that an elevated pretreatment ratio of substance P to 5-HIAA/creatinine >70 is associated with the development of delayed vomiting induced by MEC.
Literatur
1.
Zurück zum Zitat American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679 American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679
2.
Zurück zum Zitat Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 104:1848–1853PubMedCrossRef Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 104:1848–1853PubMedCrossRef
3.
Zurück zum Zitat Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S (2004) Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 3:CD003445PubMed Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S (2004) Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 3:CD003445PubMed
4.
Zurück zum Zitat Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177PubMedCrossRef Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177PubMedCrossRef
5.
Zurück zum Zitat Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 15:4112–4119CrossRef Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 15:4112–4119CrossRef
6.
Zurück zum Zitat Veyrat-Follet C, Farinotti R, Palmer JL (1997) Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs 53:206–234PubMedCrossRef Veyrat-Follet C, Farinotti R, Palmer JL (1997) Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs 53:206–234PubMedCrossRef
7.
Zurück zum Zitat Cubeddu LX (1996) Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53(Suppl 1):18–25PubMedCrossRef Cubeddu LX (1996) Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53(Suppl 1):18–25PubMedCrossRef
8.
Zurück zum Zitat Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174–1178PubMed Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174–1178PubMed
9.
Zurück zum Zitat Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945–952CrossRef Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945–952CrossRef
10.
Zurück zum Zitat Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: a double-blind randomized comparative trial of ondansetron (GR38032F) versus placebo. Eur J Cancer 29A(Suppl 1):35–38CrossRef Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: a double-blind randomized comparative trial of ondansetron (GR38032F) versus placebo. Eur J Cancer 29A(Suppl 1):35–38CrossRef
11.
Zurück zum Zitat Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290–2300PubMedCrossRef Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290–2300PubMedCrossRef
12.
Zurück zum Zitat Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758298 and MK-0869. Cancer 94:3032–3041PubMedCrossRef Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758298 and MK-0869. Cancer 94:3032–3041PubMedCrossRef
13.
Zurück zum Zitat Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767PubMed Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759–1767PubMed
14.
Zurück zum Zitat Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:90–195CrossRef Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:90–195CrossRef
15.
Zurück zum Zitat Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72:2239–2241PubMedCrossRef Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72:2239–2241PubMedCrossRef
16.
Zurück zum Zitat Higa GM, Auber ML, Altaha R, Kurian S, Hobbs G (2009) Concordance between substance P levels and antiemetic guidelines. J Support Oncol 7:38–142 Higa GM, Auber ML, Altaha R, Kurian S, Hobbs G (2009) Concordance between substance P levels and antiemetic guidelines. J Support Oncol 7:38–142
17.
Zurück zum Zitat Higa GM, Auber ML, Altaha R, Piktel D, Kurian S, Hobbs G, Landreth K (2006) 5-hydroxyindole acetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Pract 12:201–209PubMedCrossRef Higa GM, Auber ML, Altaha R, Piktel D, Kurian S, Hobbs G, Landreth K (2006) 5-hydroxyindole acetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Pract 12:201–209PubMedCrossRef
18.
Zurück zum Zitat Kris MG, Hesketh PJ, Herrstedt J et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96PubMedCrossRef Kris MG, Hesketh PJ, Herrstedt J et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85–96PubMedCrossRef
19.
Zurück zum Zitat Kris MJ, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guidelines for antiemetics in oncology. J Clin Oncol 24:2932–2947PubMedCrossRef Kris MJ, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guidelines for antiemetics in oncology. J Clin Oncol 24:2932–2947PubMedCrossRef
21.
Zurück zum Zitat Yanaihara C, Sato H, Hirohashi M, Sakagami M, Yamamoto K (1976) Substance P radioimmunoassay using N-a-tyrosyl-substance P and demonstration of the presence of substance P-like immunoreactivity in human blood and porcine tissue extracts. Endocrinol Jap 23:457–463CrossRef Yanaihara C, Sato H, Hirohashi M, Sakagami M, Yamamoto K (1976) Substance P radioimmunoassay using N-a-tyrosyl-substance P and demonstration of the presence of substance P-like immunoreactivity in human blood and porcine tissue extracts. Endocrinol Jap 23:457–463CrossRef
22.
Zurück zum Zitat Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N (2011) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 68:653–659PubMedCrossRef Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N (2011) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 68:653–659PubMedCrossRef
23.
Zurück zum Zitat Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26–31PubMedCrossRef Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26–31PubMedCrossRef
24.
Zurück zum Zitat Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408–2416PubMed Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408–2416PubMed
25.
Zurück zum Zitat Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431PubMedCrossRef Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431PubMedCrossRef
26.
Zurück zum Zitat Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830PubMedCrossRef Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830PubMedCrossRef
Metadaten
Titel
Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting
verfasst von
Gerald M. Higa
Miklos L. Auber
Gerry Hobbs
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1402-2

Weitere Artikel der Ausgabe 11/2012

Supportive Care in Cancer 11/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.